According to The Insight Partners' research, the Asia Pacific Injectable Drug Delivery Market was valued at US$ 7,266.8 Million in 2024 and is expected to reach US$ 13,319.1 Million by 2031, registering a CAGR of 9.2% from 2025 to 2031.
Expanding role of injectable immunotherapies in cancer treatment and use of biodegradable polymers & green packaging in Injectable Drug Systems are among the critical factors driving the growth of injectable drug delivery market.
By 2031, biodegradable polymers and eco-friendly packaging are likely to mitigate plastic waste from over 16 billion syringes discarded annually, aligning with the WHO's zero-pollution ambitions and reducing environmental footprints in pharmaceutical supply chains. Polyhydroxyalkanoates (PHAs) and poly(vinyl alcohol) (PVA)-based composites, derived from microbial fermentation, offer fully degradable alternatives to glass and polypropylene vials, degrading in soil within 6 months without microplastic release. A 2025 NIH study on PHA-encapsulated injectables for chronic pain management demonstrated 95% drug stability over 12 months while cutting carbon emissions by 60% compared to conventional materials. WHO reports that healthcare contributes 5% of global emissions, with injectables accounting for 10% of medical waste in low-resource settings, exacerbating pollution in regions treating 80% of the world's 1.9 billion chronic disease cases. Secalin-based films for vaccine packaging extend shelf-life by 30% via antioxidant properties while being compostable, as validated in 2025 trials for polio campaigns. Advanced biocompatible polymers, such as those in low-consumption protocols, could save 800 tons of waste and US$ 500 million yearly by optimizing syringe volumes. Future developments will integrate 3D-printed green polypills with injectable boosters, per EMA sustainability directives, fostering circular economies through recyclable LNPs. Barriers such as scalability will be addressed via biotech partnerships, potentially halving pharma's 2025 waste baseline. This trend complies with the EU Green Deal targets, aiming for 55% emission cuts by 2030. It enhances access in vulnerable areas, where improper disposal fuels disease vectors, embedding environmental stewardship into therapeutic delivery for a healthier planet.
On the flipside, stringent regulatory requirements and protracted approval processes hamper the injectable drug delivery market growth.
Asia Pacific Injectable Drug Delivery Market Segmentation Analysis:
- By Device Type, the Asia Pacific Injectable Drug Delivery Market is segmented into Conventional Drug Delivery Devices and Advanced Drug Delivery Devices. The Conventional Drug Delivery Devices segment is projected to expand at a CAGR of 8.0% during 2025 - 2031.
- By Formulation, the Asia Pacific Injectable Drug Delivery Market is segmented into Conventional Drug Delivery, Novel Drug Delivery, and Long Acting Injectable Formulations. The Conventional Drug Delivery segment is projected to expand at a CAGR of 8.6% during 2025 - 2031.
- By Formulation Packaging, the Asia Pacific Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment is projected to expand at a CAGR of 8.9% during 2025 - 2031.
- By Therapeutic Application, the Asia Pacific Injectable Drug Delivery Market is segmented into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Other Therapeutic Applications. The Diabetes segment is projected to expand at a CAGR of 9.3% during 2025 - 2031.
- By Route of Administration, the Asia Pacific Injectable Drug Delivery Market is segmented into Sub-cutaneous, Intramuscular, Intravenous, and Other Route of Administration. The Sub-cutaneous segment is projected to expand at a CAGR of 9.2% during 2025 - 2031.
- By Usability, the Asia Pacific Injectable Drug Delivery Market is segmented into Disposable Injectors and Re-usable Injectors. The Disposable Injectors segment is projected to expand at a CAGR of 7.8% during 2025 - 2031.
- By End User, the Asia Pacific Injectable Drug Delivery Market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. The Pharmaceutical and Biopharma Companies segment is projected to expand at a CAGR of 7.8% during 2025 - 2031.
By country, the Asia Pacific Injectable Drug Delivery Market is categorized into China, Japan, India, Australia, South Korea, Rest of APAC. China is projected to expand at a CAGR of 9.5% during 2025 - 2031.
Key players operating in the Injectable Drug Delivery Market are B Braun SE, Terumo Corp, Cardinal Health Inc, Phillips-Medisize, Nipro Corp, Gerresheimer AG, West Pharmaceutical Services Inc, Schott AG, Becton Dickinson and Co, Kindeva Drug Delivery LP, among others.
- Aug 2025, SCHOTT, a global pioneer in specialty glass, announced the addition of syringe and cartridge glass tubing to its existing state-of-the-art manufacturing capabilities in Jambusar, Gujarat. This also marks a significant milestone in India's glass primary pharmaceutical packaging landscape, reinforcing SCHOTT's commitment to the 'Make in India' initiative.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com